Brief: Karolinska Development's Dilafor Gets Patent In US
03/10/2025 07:31
Oct 3 (Reuters) - Karolinska Development AB KDEV.ST: KAROLINSKA DEVELOPMENT’S PORTFOLIO COMPANY DILAFOR RECEIVES PATENT IN THE US FOR TAFOXIPARIN IN PRIMING OF LABOR PATENT PROVIDES KEY INTELLECTUAL PROPERTY PROTECTION IN US UNTIL AT LEAST MAY 2043 Source text: ID:nGNE4BGn8n Further company coverage: KDEV.ST (Gdansk Newsroom) ((Gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Kdventures AB
See all newsRefile: BRIEF-Umecrine Cognition Gets Notice Of Allowance In US
Brief: KDventures' Modus Therapeutics Pauses Enrollment In Phase 2A Study
Brief: KDventures' AnaCardio Raises €62.5 Million
Brief: Kdventures' Umecrine Cognition Gets Two USPTO Notices Of Allowance For Patent Applications
Brief: Kdventures' Modus Therapeutics Carries Out Directed Issue